Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities

H. Lundbeck A/S hereby reports transactions made by executives and persons and
legal entities closely associated to them with shares in H. Lundbeck A/S and
linked securities, cf. section 28a of the Danish Securities Trading Act.

The list is based on reports received by H. Lundbeck A/S from the company´s
executives today or yesterday.Persons or entities under an obligation to report
are defined as members of the Executive Management and the Supervisory Board of
H. Lundbeck A/S and persons/entities closely associated to them.

Name: Ulf Wiinberg

Job position of the executive: President and CEO

ID code (ISIN code): DK 0010287234

Description of the security: Share

Nature of the transaction: Purchase of shares

Date of trading: 12 August 2011

Market on which the trading was effected: Nasdaq OMX Copenhagen

Number of traded securities: 5,000 shares

Market price of securities traded: DKK 613,500

Closely associated persons/entities means inter alia:

* spouse or cohabitant
* children below the age of 18
* legal entities in which the insider has a controlling influence

The content of this release will have no influence on the Lundbeck Group´s
financial expectations for 2011.

Lundbeck contacts

Investors: Media:

Palle Holm Olesen Mads Kronborg

Chief Specialist, Investor Relations Media Relations Manager

[e-mail] [e-mail]

[phone] [phone]

Magnus Thorstholm Jensen Simon Mehl Augustesen

Investor Relations Officer International Media Specialist

[e-mail] [e-mail]

[phone] [phone]

Jacob Tolstrup

Vice President

[e-mail]

[phone]

About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical
company highly committed to improving the quality of life for people suffering
from central nervous system (CNS) disorders. For this purpose, Lundbeck is
engaged in the research, development, production, marketing and sale of
pharmaceuticals across the world. The company´s products are targeted at
disorders such as depression and anxiety, schizophrenia, insomnia, epilepsy and
Huntington´s, Alzheimer´s and Parkinson´s diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today
Lundbeck employs approximately 5,900 people worldwide. Lundbeck is one of the
world´s leading pharmaceutical companies working with CNS disorders. In 2010,
the company´s revenue was DKK 14.8 billion (approximately EUR 2.0 billion or USD
2.6 billion). For more information, please visit www.lundbeck.com.

Release no 444:
http://hugin.info/130085/R/1538472/469913.pdf

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: H. Lundbeck A/S via Thomson Reuters ONE

[HUG#1538472]

Wertpapiere des Artikels:
DK0010287234